Semma Therapeutics has closed an oversubscribed $114 million Series B round to help fund the development of its encapsulated stem cell-derived islet therapy for Type I diabetes.
The Cambridge, Mass.-based company reported that it plans to use the newly-acquired funds to bring its cell therapy through clinical proof-of-concept studies, as well as explore other regenerative medicine therapies.
Get the full story at our sister site, Drug Delivery Business News.
The post Semma Therapeutics closes $114m round to advance cell therapy for Type I diabetes appeared first on MassDevice.
from MassDevice http://ift.tt/2nj1IBC
Cap comentari:
Publica un comentari a l'entrada